Adalimumab

Humira, Hadlima, Hyrimoz

Biologic • TNF-alpha inhibitor

Hepatotoxic

Half-life

14 days

Protein Binding

N/A

Metabolized By

Proteolytic degradation

External

Fully human monoclonal antibody that binds and neutralizes TNF-alpha

Drug Class

Biologic

Subclass

TNF-alpha inhibitor

HumiraHadlimaHyrimoz

Half-life

14 days

Time for plasma concentration to decrease by 50%

Protein Binding

N/A

Fraction bound to plasma proteins

Therapeutic Index

Wide

Margin between therapeutic and toxic doses